Teriparatide Peptideyog ib qho tshwj xeeb recombinant peptide osteoanabolic tshuaj. Nws cov txiaj ntsig tseem ceeb yog los ntawm nws cov qauv peptide molecular meej: ntau dua li tsis yog cov tshuaj hormones tsis zoo, nws yog ntu peptide nquag uas rov ua dua 1-34 amino acids ntawm N-qhov kawg ntawm tib neeg endogenous parathyroid hormone (PTH). Nws khaws cov haujlwm tseem ceeb ntawm kev txhawb nqa cov pob txha thaum tsis txhob muaj kev cuam tshuam tsis zoo cuam tshuam nrog kev siv lub sijhawm ntev ntawm cov tshuaj hormones, embodying tus yam ntxwv ntawm cov tshuaj peptide- ua tau zoo, lub hom phiaj tshwj xeeb, thiab tsis muaj tshuaj lom.
Peb Cov Khoom Muag Khoom
Teriparatide COA
Daim Ntawv Thov Kev Kho Mob hauv Fibrous Dysplasia (FD) ntawm Pob Txha
Fibrous dysplasia ntawm cov pob txha yog ib qho qog nqaij hlav zoo -zoo li pob txha lesion tshwm sim los ntawm somatic activating mutations ntawm GNAS noob. Nws cov yam ntxwv tseem ceeb ntawm cov kab mob pathological yog hloov cov pob txha ib txwm muaj cov ntaub so ntswg tsis zoo thiab cov pob txha woven, ua rau txo cov pob txha loj, cuam tshuam cov pob txha microarchitecture, thiab nce pob txha fragility. Feem ntau cov kev kho mob tshwm sim muaj xws li mob pob txha, skeletal deformity, thiab pathological fractures.
Hauv cov xwm txheej hnyav, nws tuaj yeem cuam tshuam kev sib koom tes lossis txawm tias cov hlab ntsha thiab cov hlab ntsha uas nyob ib sab, cuam tshuam rau cov neeg mob lub neej zoo. Kev kho mob rau FD feem ntau yog kev phais mob (kho thiab pob txha grafting, kho deformity) thiab cov tsos mob analgesia. Txawm li cas los xij, cov kev xaiv kho mob tsuas yog txwv rau cov neeg mob uas muaj kab mob ntau yam, cov neeg tsis kam mus phais, lossis cov neeg uas muaj kev rov ua haujlwm tom qab. Nrog nws cov teebmeem osteoanabolic muaj zog,Teriparatide Peptidemuab lub tswv yim tshiab rau kev tswj FD, tshwj xeeb tshaj yog hauv kev txhim kho pob txha zoo, txo cov pob txha mob, thiab txo qis kev pheej hmoo ntawm pob txha.
Pathogenesis thiab kev kho mob nyuaj ntawm Fibrous Dysplasia
Lub hauv paus pathogenesis ntawm FD suav nrog kev hloov pauv ntawm somatic activating hauv GNAS gene, ua rau GTPase kev ua haujlwm tsis zoo ntawm cov encoded G protein -subunit (Gs ), uas nyob rau hauv lem ua rau overactivation ntawm cyclic adenosine monophosphate (cAMP) / protein kinase A (PKA) teeb liab txoj kev. Qhov no ua rau muaj qhov txawv txav ntawm cov pob txha pob txha mesenchymal qia hlwb (BMSCs) thiab kev cuam tshuam osteogenic sib txawv, thaum kawg ua rau cov pob txha loj heev ntawm cov nqaij mos thiab cov pob txha tsis paub tab uas hloov cov pob txha ib txwm muaj.
Xws li kev hloov pauv pathological cuam tshuam txo cov pob txha txhua yam lub zog thiab ua rau muaj kev puas tsuaj rau cov kab mob pathological. Lub caij no, cov pob txha txawv txav ua rau cov hlab ntsha peripheral xaus, ua rau mob pob txha tsis tu ncua thiab ua rau muaj kev txwv tsis pub txav mus los.
Kev tswj xyuas kev kho mob tam sim no ntawm FD ntsib ntau yam teeb meem: rau cov kab mob monofocal, cov kab mob hauv cheeb tsam, kev kho mob thiab cov pob txha grafting yog thawj zaug - kab kev kho mob, tab sis qhov kev rov ua haujlwm tom qab rov qab yog siab (kwv yees li 15% - 30%), thiab graft fusion yog nyob ntawm cov pob txha hauv paus zoo. Rau cov kab mob sib kis los yog cov uas muaj qhov hnyav-cov pob txha los yog cov pob txha craniofacial, kev phais yog qhov nyuaj thiab cuam tshuam heev, ua kom tiav kev txiav txim siab tsis tuaj yeem.
Txawm hais tias bisphosphonates tuaj yeem txo qhov mob pob txha, lawv tsis tuaj yeem thim rov qab cov pob txha microarchitectural puas los yog txo qhov kev pheej hmoo ntawm cov pob txha puas. Nonsteroidal anti-cov tshuaj tiv thaiv kab mob tsuas yog muab kev kho mob ib ntus xwb yam tsis tau tsom rau qhov tshwm sim, thiab kev siv sijhawm ntev - tuaj yeem ua rau mob plab hnyuv.
Yog li ntawd, muaj qhov xav tau kev kho mob sai sai rau tus neeg sawv cev kho mob uas tuaj yeem txhim kho pob txha zoo, txhim kho pob txha muaj zog, thiab txo qis FD kev loj hlob. Qhov tshwm sim ntawm nws muab cov lus cog tseg rau qhov teeb meem no.
Cov ntaub ntawv qhov chaw: PMC tsab xov xwm (Kev kuaj mob thiab kev tswj xyuas ntawm Monostotic Fibrous Dysplasia ntawm Tibia hauv Tus Neeg Mob Hluas: Ib Daim Ntawv Qhia Txog); MDPI tsab xov xwm (PTHrP Modulates lub Proliferation thiab Osteogenic sib txawv ntawm Craniofacial Fibrous Dysplasia-Drived BMSCs).
Mechanism of Action hauv FD Treatment
Targeting lub pathological nta ntawm FD, nws exerts kev kho mob los ntawm ntau txoj kev, nrog rau cov tseem ceeb ua ntawm kev txhim kho qhov txawv ntawm BMSCs txawv txav, txhawb nqa ib txwm pob txha tsim, thiab inhibiting txawv txav cov ntaub so ntswg proliferation. Cov txheej txheem tshwj xeeb poob rau hauv peb pawg loj.
Ua ntej, nws tswj cov kev taw qhia sib txawv ntawm BMSCs. BMSCs hauv FD cov neeg mob qhia qhov txawv txav txawv txav, nrog kev sib txawv ntau dhau mus rau fibroblasts thiab kev cog lus osteogenic tsis txaus.
Los ntawm kev khi rau PTH receptors ntawm BMSCs,Teriparatide Peptideactivates Wnt/ -catenin signaling pathway thiab suppresses cAMP/PKA pathway activation, yog li kho qhov txawv txav ntawm BMSC. Qhov no coj BMSCs mus rau cov kab mob osteogenic, txo qis cov nqaij mos fibrous tsim, nce osteoblast tus naj npawb thiab kev ua si, thiab pab txhawb kev kho pob txha.
Thib ob, nws txhim kho pob txha microarchitecture thiab txhim kho pob txha muaj zog. Lesional pob txha nyob rau hauv FD yog dominated los ntawm cov tsis paub tab woven pob txha thiab fibrous cov ntaub so ntswg, nrog sparse, fractured trabeculae thiab thinned cortices, uas ua rau lub markedly txo txhua yam zog.
Kev tswj xyuas tsis tu ncua ntawm nws txhawb nqa osteoblasts los ua ke cov pob txha matrix, nce trabecular thickness, pob txha ntim feem, thiab tus lej trabecular thaum txo qis kev sib cais. Nws kho cov pob txha puas microarchitecture thiab txhawb txoj kev hloov ntawm cov pob txha woven rau hauv cov pob txha laus lamellar, txhawb kev txhim kho cov pob txha pob txha thiab txo qis kev pheej hmoo ntawm kev puas tsuaj.
Thib peb, nws relieves mob pob txha thiab txhim kho cov neeg mob mus. Cov pob txha mob hauv FD feem ntau tshwm sim los ntawm cov hlab ntsha tawg los ntawm cov pob txha txawv txav thiab kev tsis sib haum xeeb los ntawm microarchitectural cuam tshuam. Nws txo qis neural compression los ntawm kev txhawb nqa cov pob txha ib txwm muaj thiab kho cov pob txha puas. Nws cov nyhuv osteoanabolic kuj tseem txhim kho pob txha kev ruaj ntseg, txo qhov hnyav - mob hnyav, yog li txhim kho kev txav mus los thiab lub neej zoo. Cov kev tshawb fawb hauv vitro tau lees paub tias nws txhim kho qhov sib txawv osteogenic ntawm FD tus neeg mob - tau txais BMSCs thiab txo qhov kev qhia ntawm cov kab mob ntawm cov nqaij mos txawv txav.
Cov ntaub ntawv qhov chaw: MDPI tsab xov xwm (PTHrP Modulates qhov kev loj hlob thiab Osteogenic sib txawv ntawm Craniofacial Fibrous Dysplasia-Drived BMSCs); Suav Cov Kws Tshaj Lij Pom Zoo rau Teriparatide rau Osteoporotic Fractures (2024 Edition) (Suav Phau Ntawv Kho Mob Tag Nrho -}ip Cov Ntaub Ntawv Phau Ntawv Qhia StatPearls).
Daim ntawv thov hauv Kev Txhim Kho Kev ruaj ntseg ntawm Orthopedic Implants
Orthopedic implants (xws li cov pob qij txha, pob txha kho pob txha, pob txha pob txha scaffolds, thiab lwm yam) tau siv dav hauv kev phais orthopedic nrog rau kev txhim kho pob txha, kev sib koom ua ke thiab kho pob txha. Lawv qhov ruaj khov ncaj qha txiav txim siab qhov tshwm sim ntawm kev phais thiab tus neeg mob prognosis. Kev cog qoob loo tsis txaus yuav ua rau cov cog cog qoob loo, hloov pauv thiab tawg, uas ua rau muaj teeb meem ntxiv xws li kev phais tsis ua haujlwm, pob txha periprothetic thiab kab mob. Cov teeb meem no feem ntau xav tau kev kho dua tshiab, ua rau cov neeg mob kev txom nyem thiab cov nqi kho mob.Nrog nws cov nyhuv osteoanabolic muaj zog,Teriparatide Peptidetuaj yeem txhawb osseointegration ntawm cov pob txha cog thiab tus tswv tsev thiab txhim kho cov pob txha zoo nyob ib puag ncig ntawm kev cog hniav, yog li ua kom muaj kev ruaj ntseg ntev ntawm orthopedic implants, txo qhov tshwm sim ntawm cov teeb meem thiab optimizing phais prognosis.
Cov ntaub ntawv qhov chaw: Tuam Tshoj Cov Ntaub Ntawv Kho Mob Query Platform (Fuqin'ao Teriparatide); Tuam Tshoj Cov Ntaub Ntawv Kho Mob Query Platform (Recombinant Teriparatide rau Txhaj Tshuaj); NCBI Bookshelf (Teriparatide - StatPearls).
Kev Tsis Pom Zoo
Cov kev phiv tshwm sim feem ntau yog cuam tshuam nrog kev txhaj tshuaj - qhov chaw thiab cov tshuaj tiv thaiv kab mob. Kev txhaj tshuaj- qhov chaw tshwm sim muaj xws li mob, o, erythema, bruising hauv zos, pruritus, thiab los ntshav me me, uas feem ntau yog ib ntus thiab daws tau maj mam nrog kev kho mob ntxiv; rotating qhov chaw txhaj tshuaj tuaj yeem txo cov kev cuam tshuam zoo li no. Cov tshuaj tiv thaiv kab mob feem ntau muaj xws li xeev siab, mob ceg, mob taub hau, kiv taub hau, palpitations, anemia, dyspnea, thiab kev nyuaj siab, nrog cov xwm txheej zoo ib yam li cov neeg hauv pawg placebo. Feem ntau tshwm sim thaum ntxov ntawm kev kho mob, mob me me, thiab tsis xav tau kev kho mob ntxiv.
Tsis tas li ntawd, nws tuaj yeem ua rau nce me ntsis hauv cov ntshav cov calcium thiab uric acid. Hauv kev sim tshuaj ntsuam xyuas, 2.8% ntawm cov neeg mob muaj cov ntshav uric acid ntau tshaj qhov kev txwv ntawm ib txwm muaj, tab sis qhov no tsis ua rau muaj mob gout, mob caj dab, lossis urolithiasis. Hypercalcemia feem ntau yog ib ntus thiab yuav tsum tsis muaj kev tswj xyuas tshwj xeeb. Txawm li cas los xij, yog tias cov neeg mob tsim cov tsos mob ntsig txog hypercalcemia (xws li xeev siab, ntuav, cem quav, polyuria), kev kho mob yuav tsum tau nrhiav kom sai li sai tau rau kev hloov tshuaj lossis kev kho mob.
Cov ntaub ntawv qhov chaw: MDPI, Teriparatide Therapy as an Adjuvant for Tissue Engineering and Integration of Biomaterials;Journal of Orthopedic Case Reports, Teriparatide Treatment Improved Loosening of Cementless Total Knee Arthroplasty: Ib Daim Ntawv Qhia Txog.
I. High-Kev Ua Haujlwm Ua Kua Dej Chromatography (HPLC): Kev Ntsuam Xyuas Yooj Yim rau Cov Ntsiab Lus thiab Kev Ncauj Lus
High -kev ua tau zoo kua chromatography yog feem ntau siv cov txheej txheem kev tshuaj ntsuam xyuas yooj yim rau nws, feem ntau yog siv rau kev txiav txim siab cov ntsiab lus peptide thiab kev tshuaj ntsuam xyuas purity. Nws muaj qhov zoo ntawm kev ua haujlwm yooj yim, zoo rov tsim dua, thiab siab rhiab heev. Kev kuaj pom feem ntau yog ua los ntawm C18 kem (piv txwv li, Kromasil C18, 4.6 mm × 250 mm, 5 μm), nrog rau theem mobile uas muaj 0.05 mol·L⁻¹ potassium chloride tov (hloov rau pH 4.5 nrog phosphoric acid) thiab acetonitrile ratio 25.75 ntawm acetonitrile.
Tus nqi ntws yog tswj ntawm 1.0 mL·min⁻¹, nrhiav kom tau wavelength ntawm 210 nm, kem kub ntawm chav tsev kub, thiab ntim ntim ntawm 20 μL. Txoj kev no ua rau muaj kev sib cais zoo ntawm nws los ntawm impurities. Nws qhia tau hais tias zoo linearity (r=0.9999) nyob rau hauv lub concentration ntau ntawm 0.05–0.84 mg·mL⁻¹, tso cai rau kev txiav txim siab ntawm cov ntsiab lus ntawm cov tshuaj thiab kev tshuaj ntsuam purity ua ntej. Tsis tas li ntawd, raws li qhov yuav tsum tau muaj ntawm European Pharmacopoeia (EP 9.0), hydrophilic silica gel packed kem tuaj yeem siv los cais cov impurities nrog molecular hnyav dua li teriparatide, kom ntseeg tau tias muaj kev sib cais zoo.
Cov ntaub ntawv qhov chaw: Kev Kawm Txuj Ci Database ntawm Hainan Medical University (Kev kawm txog kev txiav txim siab ntawm teriparatide los ntawm siab -kev ua haujlwm ua kua chromatography); Shodex Cov ntawv nyeem (Kev tshuaj xyuas ntawm Teriparatide Raws li EP Method (KW-802.5)).
II. Liquid Chromatography-High Resolution Mass Spectrometry (LC-HRMS): Kev txheeb xyuas qhov tseeb thiab kom muaj nuj nqis ntawm impurities
Vim muaj kev txwv ntawm HPLC-UV nyob rau hauv impurity identification, uas tsis tuaj yeem qhia meej cov qauv ntawm co-eluting impurities, kua chromatography- siab daws teeb meem loj spectrometry tau dhau los ua cov txheej txheem tseem ceeb rau impurity tsom xam ntawmTeriparatide Peptide. Ua ke lub zog sib cais ntawm chromatography nrog rau qhov tshwj xeeb thiab rhiab heev ntawm huab hwm coj spectrometry, txoj kev no tso cai rau kev tshawb nrhiav, kev sib cais, thiab kom muaj nuj nqis ntawm cov txheej txheem -txog thiab degradation- ntsig txog impurities, xws li oxidative degradation khoom thiab peptide fragments.
Kev sim tau lees paub tias txoj kev pom zoo linearity nyob rau hauv qhov concentration ntau ntawm 500 txog 10,000 ng / mL (r²=0.9998), nrog precision (% RSD) qis dua 2.0%. Qhov kev txwv ntawm kev tshawb nrhiav thiab kev txwv tsis pub muaj ntau npaum li tsawg li 0.02% thiab 0.05% ntawm daim ntawv thov daim ntawv thov, feem, deb tshaj qhov kev cai qhia txog kev pib (0.10%). Nws tuaj yeem txheeb xyuas qhov tsis huv xws li teriparatide oxidative degradation cov khoom thiab 1-30 amino acid fragments, muab kev txhawb nqa tseem ceeb rau kev tswj hwm tshuaj purity.
Cov ntaub ntawv qhov chaw: Lub Chaw rau Kev Tshawb Fawb Txog Kev Tshawb Fawb Txog Kev Tshawb Fawb (CRCG) Cov Ntawv Sau (Kev Kho Mob Teriparatide Kev Tswj Xyuas Zoo los ntawm Liquid Chromatography Mass Spectrometry); PubMed Literature (Validation of a kua chromatography-high- daws teeb meem huab hwm coj spectrometry txoj kev kom quantify peptide{2}}.
III. Peptide Mapping Analysis (LC-UV-MS): Kev pom zoo thiab kev ua tiav
Peptide mapping yog txoj hauv kev tseem ceeb rau kev pom zoo ntawm teriparatide. Los ntawm enzymatic hydrolysis, chromatographic sib cais, thiab hyphenated mass spectrometry, nws ua tiav tag nrho cov ntaub ntawv pov thawj ntawm peptide ib ntus thiab kev pom zoo ntawm cov qauv thawj. Cov txheej txheem yog raws li nram no: teriparatide yog thawj zaug rau enzymatic hydrolysis, ces cov hydrolyzate fragments yog sib cais siv ntau kab (piv txwv li, C18, phenylhexyl kab), thiab thaum kawg txheeb xyuas los ntawm ib tug siab - daws teeb meem QTOF huab hwm coj spectrometer, ua tiav 100% kev pab them nqi sequence.
Los ntawm kev sib piv cov peptide maps (lub sij hawm tuav, ncov qhov siab, kev daws teeb meem) ntawm cov qauv thiab cov qauv siv, cov qauv no lees paub cov qauv ntawm teriparatide thiab txheeb xyuas cov khoom hloov pauv xws li oxidation thiab deamidation, kom ntseeg tau tias cov qauv tshuaj zoo ib yam nrog cov khoom nquag ntawm cov tshuaj parathyroid. Nws yog cov txheej txheem tseem ceeb rau kev sib piv cov qauv sib xws ntawm cov tshuaj siv tshuaj thiab cov tshuaj siv tau teev tseg.
Cov ntaub ntawv qhov chaw: Sigma-Aldrich Literature (Teriparatide Mapping Analysis los ntawm LC-UV- MS); MDPI Cov ntawv nyeem (Thawj Generic Teriparatide: Cov Qauv thiab Cov Khoom Siv Zoo ib yam rau Nws Cov Khoom Siv Tshuaj).
IV. LC-MS/MS Method: Kev kuaj pom hauv cov qauv kuaj ntshav
Rau kev soj ntsuam xyuas, kev txiav txim siab ntawm teriparatide concentration hauv tib neeg cov ntshav yog xav tau, uas yog siv ultra-kev ua haujlwm siab chromatography-tandem huab hwm coj spectrometry (LC-MS/MS) feem ntau. Hauv txoj kev no, teriparatide hauv cov ntshav yog muab rho tawm los ntawm cov khoom siv-theem rho tawm, nrog nas PTH 1-34 fragment raws li tus qauv sab hauv, thiab kuaj pom siv ntau qhov kev saib xyuas ion. Lub sijhawm ua haujlwm tag nrho tsuas yog 4.0 min, nrog qhov sib txawv ntawm 15.07–913.3 pg / mL (kev sib raug zoo coefficient Ntau dua lossis sib npaug rau 0.99). Ob qho tib si qhov tseeb thiab qhov tseeb ua tau raws li qhov yuav tsum tau ua rau kev soj ntsuam bioanalytical. Yog tias tsis xav tau cov tshuaj tiv thaiv kab mob, txoj kev no txo qis kev cuam tshuam los ntawm kev tsis sib xws los ntawm kev sib khi tshwj xeeb. Nws tau ua tiav hauv kev tshawb fawb txog bioequivalence, ua kom muaj kev soj ntsuam sai ntawm cov qauv ntshav ntau thiab muab cov ntaub ntawv txhawb nqa rau kev hloov kho cov tshuaj ntau npaum li cas.
Cov ntaub ntawv qhov chaw: PubMed Literature (Bioanalytical method development and validation of highly selective and sensitive LC-MS/MS method for determination of teriparatide in human serum).
Cim npe nrov: Tuam Tshoj teriparatide peptide manufacturers, lwm tus neeg
